sorafenib has been researched along with leupeptins in 3 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (leupeptins) | Trials (leupeptins) | Recent Studies (post-2010) (leupeptins) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 3,891 | 4 | 1,106 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chao, CC; Kuo, TC; Lu, HP | 1 |
| Bertolotto, C; Bourcier, C; Grépin, R; Griseri, P; Mazure, N; Pagès, G | 1 |
| Harada, M; Honma, Y; Shimizu, S; Takehara, T | 1 |
3 other study(ies) available for sorafenib and leupeptins
| Article | Year |
|---|---|
The tyrosine kinase inhibitor sorafenib sensitizes hepatocellular carcinoma cells to taxol by suppressing the HURP protein.
Topics: Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Eukaryotic Initiation Factor-4E; Humans; Leupeptins; Liver Neoplasms; Neoplasm Proteins; NF-kappa B; Niacinamide; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-rel; Pyridines; Sorafenib | 2011 |
Constitutive ERK activity induces downregulation of tristetraprolin, a major protein controlling interleukin8/CXCL8 mRNA stability in melanoma cells.
Topics: Animals; Antibodies; Antineoplastic Agents; Apoptosis; Autophagy; Benzamides; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL1; Chemokine CXCL5; Dichlororibofuranosylbenzimidazole; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression; Genes, Reporter; Half-Life; Humans; Immunotherapy, Active; Interleukin-8; Leupeptins; MAP Kinase Kinase Kinases; Melanoma; Membrane Proteins; Mice; Mice, Inbred BALB C; Microtubule-Associated Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins; Pyridines; Receptors, Interleukin-8B; RNA Stability; RNA, Messenger; RNA, Small Interfering; Sorafenib; Transfection; Tristetraprolin; Tumor Cells, Cultured; Vaccination | 2011 |
Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Down-Regulation; Drug Synergism; Humans; Leupeptins; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Oligopeptides; Phenylurea Compounds; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib | 2014 |